Dr Shane Olwill | Vice President of Development
Pieris Pharmaceuticals

Dr Shane Olwill, Vice President of Development, Pieris Pharmaceuticals

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

Appearances:



WIC 2017 Day 1, Tuesday 31st October 2017 @ 17:10

Costimulatory T-Cell engagement by the 4-1BB/HER2 bispecific PRS-343 for tumor localized activation of the immune system

  • Generation of the 4-1BB/HER2 bispecific, PRS-343
  • In vitro and in vivo characterisation of PRS-343
  • IND enabling studies to support clinical evaluation of PRS-343
 

back to speakers